The company reported $213 million in net earnings this past quarter, compared to $325 million in 2012. The drop was due largely to a $170 million charge from the voluntary recalls of the Rejuvenate and ABG II modular-neck hip stems.
Net sales reached $2.2 billion, up from $2.1 billion last year. Sales from spine and neurotechnology devices increased 5.4 percent from $393 million to $414 million.
More Articles on Devices:
ulrich medical releases uCerv Interbody Spine Device for US Markets
Medtronic to Market Amgen’s Prolia Spine Device for Women at Risk of Osteoporosis-Related Fractures
8 Recent Leadership & Executive Moves at Spine, Orthopedic Device Companies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
